-
Nature Sub-Journal: Chinese scholars achieve true early screening of colorectal cancer based on fecal microbial markers
Time of Update: 2021-06-01
Professor Zhu Lixin's team from the Institute of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-sen University and his joint research team integrated healthy controls, colonic adenoma (CRA) and colorectal from multiple research centers The fecal microbial sequencing data of a total of 775 samples of cancer (CRC) have been systematically studied for early diagnosis and screening of colorectal cancer (CRC) based on microbial markers.
-
BMJ: Family members have a history of intestinal polyps, and the risk of colorectal cancer is 16 times higher!
Time of Update: 2021-06-01
Recently, the top international medical journal BMJ published a large retrospective clinical study from Sweden, which included a total of 401,813 cases nationwide in Sweden, on the history of intestinal polyps and/or colorectal cancer of the first-degree relatives of these groups After a systematic analysis, it was found that after adjusting for related interference factors, even if there is no family history of colorectal cancer, people with a family history of colorectal polyps are more likely to develop colorectal cancer!
-
Data comparison of 21 countries in the past 20 years: the difference is too big!
Time of Update: 2021-06-01
▲In countries where screening programs (A) have been implemented early and screenings have become widespread in recent years (B), the age-standardized incidence rate (blue line-male, red line-female) and mortality rate (green line-) of colorectal cancer Male, purple line-female) change trend.
-
Express | Tumor size can be reduced in 28 days!
Time of Update: 2021-06-01
"For more rare disease related knowledge and research progress, please click to visit our mini program reference materials: [1] NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial.
Retrieved May 26, 2021, from -reduction-in-p-erk-a-key-biomarker-driving-neurofibroma-tumor-growth-in-positive-data-from-a-28-day-phase-2a-clinical-trial-301299521.
-
Br J Cancer: TP53 mutation increases radiotherapy resistance of rhabdomyosarcoma and Ewing's sarcoma
Time of Update: 2021-06-01
In this study, the researchers aimed to determine the TP53 mutation status and related clinical phenotypes of p53 signaling pathway changes in RMS and ES patients undergoing radiotherapy.
-
The American Cancer Society (ACS) authoritatively released: Nearly half of cancer occurrences and deaths can be prevented!
Time of Update: 2021-06-01
BJ Haem: Family aggregation of early-onset hematological malignancies CLIN CANCER RES: Afatinib VS Afatinib + Cetuximab as the first-line treatment option for EGFR-mutant non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung) Phase II randomized trial 01 First-line advanced NSCLC New treatment plan!
-
Significant progress in malignant pleural mesothelioma (MPM)!
Time of Update: 2021-06-01
com" target="_blank">/ --Ono Pharmaceutical recently announced that the Japanese regulatory agency has approved the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, nivolumab) combined with anti-CTLA-4 therapy Yervoy (ipilimumab, Yi Primoma) immunocombination therapy, the first-line treatment for patients with unresectable advanced or recurrent malignant pleural mesothelioma (MPM).
-
BCMA CAR-T cell therapy! Johnson & Johnson/Nanjing Legend cilta-cel has been reviewed by the US FDA for priority review: treatment of multiple myeloma!
Time of Update: 2021-06-01
S. Food and Drug Administration (FDA) has accepted the BCMA CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel, formerly known as JNJ-4528/LCAR-B38M, LCAR- B38M CAR-T cell autologous reinfusion preparation ) and granted priority review for the biological product license application (BLA), which is used to treat adult patients with relapsed or refractory multiple myeloma (RRMM).
-
[Lymphoma Microclass|2021EHA] Ibrutinib + Rituximab in the treatment of Waldenstrom's macroglobulinemia-final analysis of 5-year follow-up
Time of Update: 2021-06-01
5 months confirmed that the progression-free survival (PFS) of ibrutinib combined with rituximab was better than placebo combined with rituximab in the treatment of patients with Waldenstrom's macroglobulinemia Monoclonal antibody group.
-
After osimertinib is resistant, how can NSCLC patients find a new way?
Time of Update: 2021-06-01
In January 2019, the first-generation EGFR-TKI gefitinib combined with the third-generation osimertinib was selected for the patients, and the efficacy evaluation was performed one month later.
-
Express | Treatment of multiple myeloma, innovative peptide-conjugated drugs Phase 3 clinical results are positive
Time of Update: 2021-06-01
▎ WuXi AppTec content team editor May 25, 2021, Oncopeptides AB announced that its peptide-conjugated drug Pepaxto (melphalan flufenamide) is in the treatment of relapsed/refractory multiple myeloma (R/R MM) phase 3 clinical trial Positive results were obtained in the experiment.
-
Case Sharing 1: Do I need adjuvant treatment after radical resection of stage Ib lung adenocarcinoma?
Time of Update: 2021-05-31
Third, in the 2020 China CSCO guidelines, it is clearly stated that for stage Ib non-small cell lung cancer, including lung cancer with high-risk factors, adjuvant chemotherapy is not recommended because it is believed that chemotherapy cannot improve the prognosis and reduce the risk of recurrence.
-
Nat Commun: Genome-wide CRISPR Screening Reveals Breast Cancer Susceptibility and mTOR/Hippo Cooperative Potential Targeted Therapy Strategy
Time of Update: 2021-05-31
The researchers used an unbiased in vivo genome-wide CRISPR knockout screening method to analyze the cancer susceptibility of TNBC at the genome-wide level and determine the interaction between carcinogenic and tumor suppressor pathways.
-
Br J Cancer: Observational cohort study reveals the effect of chemotherapy on elderly patients with early breast cancer
Time of Update: 2021-05-31
1038/s41416-021-01388-9">Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer.
-
Eur J Cancer: The role of local therapy in the presence of isolated metastases in melanoma immunotherapy: a multicenter retrospective study
Time of Update: 2021-05-31
Immunization managementThe study retrospectively collected non-uveal melanoma patients in 17 research centers in 9 countries from 2010 to 2019, who used immunotherapy for more than 12 weeks and achieved stable (SD) or partial remission (PR) or complete remission ( CR), and then an isolated metastasis occurs during or after immunotherapy.
-
Lancet Oncology: Radiotherapy and chemotherapy for locally advanced head and neck tumors: a meta-analysis of individual patient data
Time of Update: 2021-05-31
A meta-analysis of individual patient data for head and neck cancer chemotherapy (MACH-NC) showed that combined chemotherapy on the basis of radiotherapy can improve overall survival, progression-free survival and local control rates, and reduce cancer deaths.
-
How to consider the population included in the study when developing oncology drugs simultaneously across regions across the globe?
Time of Update: 2021-05-31
When drug development is designed, it will be based on previous disease literature research data or evidence , Considering factors such as clinical treatment lines, population selection, and drug use differences at home and abroad.
-
JNCI: Changes in the mortality rate of liver cancer in the past 20 years
Time of Update: 2021-05-31
This study aims to investigate the mortality and HCC staging, treatment, and overall survival prognosis trends of primary liver cancer (excluding intrahepatic cholangiocarcinoma) in the United States .
1093/jnci/djab079">The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States .
-
Lancet Oncol: Phase 3 | Comparison of the efficacy of pembrolizumab combined with chemotherapy or as a first-line treatment for advanced urothelial cancer!
Time of Update: 2021-05-31
In the platinum-based first-line chemotherapy regimen for advanced urothelial cancer, the addition of pembrolizumab does not significantly improve the therapeutic effect, and should not be widely used in the treatment of advanced urothelial cancer.
-
Lancet Oncol: Impact of Colorectal Cancer Screening Program on Incidence and Mortality of Colorectal Cancer
Time of Update: 2021-05-31
Incidence of colorectal cancer in different countriesIncidence of colorectal cancer in different countriesIn countries with long-term colonoscopy and stool examination programs (Australia, Czech Republic and Germany), the incidence of colorectal cancer has decreased over time , and the annual average percentage change (AAPC) of men and women fluctuates at -2.
